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The synthesis and conformational analysis of pseudo-thio-1,2-dimannoside are described. This molecule
mimics mannobioside (Mana(1,2)Man) and is an analog of pseudo-1,2-dimannoside, with expected
increased stability to enzymatic hydrolysis. A short and efficient synthesis was developed based on an
epoxide ring-opening reaction by a mannosyl thiolate, generated in situ from the corresponding thioac-
etate. NMR-NOESY studies supported by MM3⁄ calculations showed that the pseudo-thio-1,2-diman-
noside shares the conformational behavior of the pseudo-1,2-dimannoside and is a structural mimic of
the natural disaccharide. Its affinity for DC-SIGN was measured by SPR and found to be comparable to
the corresponding O-linked analog, offering good opportunities for further developments.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Over the past decades, an increased understanding of glycans
ability to encode biochemical information relevant to both physio-
logical and pathological conditions has stimulated a fast growth of
glycochemical research.1–4 One of the important objectives in this
field is the development of glycomimetic structures, targeted
against sugar binding proteins (called lectins) and able to alter
the read-out of sugar-encoded information. In this context,
glycomimetics have been proposed both as probes of biological
processes and for medicinal applications.5–9
Many modifications have been introduced in the structure of
carbohydrates to generate glycomimetics with improved drug-like
characteristics and stability to enzymatic degradation.10 In partic-
ular, thioglycosides have raised a great deal of interest, because the
S-glycosidic linkage is typically more resistant toward both acid-
catalyzed and enzymatic hydrolysis than O-glycosides,11,12 and
yet oxygen and sulfur share similar bonding and geometries,
allowing structural similarity. From a structural point of view,
the CAS bond is longer than the corresponding CAO bond by about
0.4 Å and the exo-anomeric effect in thiodisaccharides is less pro-
nounced than in regular sugars.13 As a result, an increased confor-
mational flexibility of the glycosidic torsions is often observed.14We previously reported that the pseudo-1,2-dimannoside 1 is a
structural mimic of 1,2-mannobioside (Mana(1,2)Man) and a
slow-reacting substrate of jack-bean mannosidase.15 Like the nat-
ural disaccharide, this molecule is an antagonist16 of the dendritic
cell receptor DC-SIGN (Dendritic Cell-Specific Intercellular adhe-
sion molecule-3 (ICAM-3)-Grabbing Non-integrin), a tetrameric
C-type lectin involved in the recognition of viruses and pathogens
at the mucosal level.17 Based on this framework, we have
developed a family of mannose-based DC-SIGN monovalent and
polyvalent ligands that were shown to work as potent inhibitors
of DC-SIGN mediated viral infections.18–21 In an effort to improve
the hydrolytic stability of 1 and to possibly simplify its synthesis,
we have examined the corresponding pseudo-thio-1,2-diman-
noside 2 (Fig. 1).
We herein report the synthesis of 2, an analysis of its
conformation based on NMR-NOESY studies (in D2O) supported
Scheme 1. One-pot synthesis of 5.
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Scheme 2. Synthesis of 4 from penta-O-acetylmannopyranose 6.
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with DC-SIGN by Surface Plasmon Resonance (SPR).
2. Results
2.1. Synthesis of the pseudo-thio-1,2-dimannoside
The synthesis of S-linked glycosides can be readily achieved by
reaction of thiolates with glycosyl donors.22 For the case at hand,
however, a more expeditious approach was employed, exploiting
nucleophilic opening of epoxide 316 (Scheme 1) by a glycosyl thiol
(1-thio sugar). Epoxide 3 is indeed a known intermediate in the
synthesis of 1, while the required glycosyl thiol can be generated
in situ from 2,3,4,6-tetra-O-acetyl-1-S-acetyl-a-D-mannopyranose
4 by selective S-deacetylation (Scheme 1).23,24 This allows, in prin-
ciple, a one-pot synthesis of the pseudo-thio-1,2-dimannoside
framework 5.
2,3,4,6-Tetra-O-acetyl-1-S-acetyl-a-D-mannopyranose 4 is a
known compound,23 which is most conveniently prepared from
penta-O-acetylmannopyranose 6 by acid catalyzed reaction with
thioacetic acid 7 (Scheme 2). The reaction affords 4 as a 9:1 a:b
mixture (61% yield), from which pure a-4 can be chromatograph-
ically isolated.
Selective thio-deacetylation of purified a-4 with excess Et2NH
affords the anomeric thiol 8, in equilibrium with the more reactive
thiolate 9 (Scheme 3). Alkylation of 9 with primary iodides has
recently been reported for the synthesis of S-linked 1,6-oligoman-
nosides.24 Alkylation with 3 (DMF, room temperature) gave almost
full conversion of the epoxide in 4 h (as evaluated by TLC and 1H
NMR monitoring), affording product 5 in 68% yield after chro-
matography. Addition of MeOH (5 mol equiv) as a supplementary
proton source did not modify the outcome of the reaction.
Compound 5was obtained as a single isomer from a completely
selective opening of 3, affording trans-diaxial cyclohexane disub-
stitution# (Scheme 1). Analysis of the coupling constants in the 1H
NMR spectrum (CD3OD, Fig. 2) clearly shows that the conformation
of the cyclohexane ring depicted in Scheme 1 and Fig. 2, carrying
both carbomethoxy groups in the equatorial position is populated
by90%. This feature is characteristic of vicinal trans-cyclohexanedi-
carboxylic acid derivatives,25 including the pseudo-1,2-dimannoside
1,15 and it allows the distal substituents in 2 to occupy the axial posi-
tion, thus mimicking the 3D features of an a-mannopyranose
residue.
The tetra-O-acetyl-pseudo-thio-1,2-dimannoside 5 was depro-
tected (MeONa in MeOH), giving 2 (R = H) in quantitative yield
(Scheme 4). To allow the synthesis of multivalent derivatives of
2, we also pursued selective functionalization of the free alcohol
group in the 10 position of 5. As a model reaction, we initially
showed that 5 could be transformed in the pivaloate 10 (pivaloyl
chloride, CH2Cl2, pyridine) and selectively deacetylated under
Zemplén conditions (0.02 M MeONa in MeOH, room temperature,
5 min) to afford 11 (Scheme 4) in quantitative yield.
This set the stage for the synthesis of 14 (Scheme 5), a pseudo-
thio-1,2-dimannoside functionalized with an azide tether, which
allows for further manipulation and transformation into multiva-
lent constructs. Compound 14 was obtained by reaction of 5 with
2,2-dimethyl-3-azido-propanoyl chloride 12, synthesized accord-
ing to a method described by Sewald et al.26 (with modifications),
to afford the ester 13 in 79% yield. Carefully controlled Zemplén
deacetylation of 13, as shown above, afforded 14 in quantitative
yield.# A second stereoisomer (3%) was observed in the 1H NMR spectrum (CDCl3) of
the crude reaction product, deriving from opening of the minor enantiomer of 3 that
has 94% e.e. This stereoisomer could be chromatographically removed from 5 (4:6
Hex:EtOAc).2.2. Conformational analysis of the pseudo-thio-1,2-dimannoside
The conformation of 2 (R = H) was investigated by NOESY
experiments; the data collected were correlated to computational
models and compared to similar information on the pseudo-1,2-
dimannoside 1.
A previous NMR study on 115 had revealed that this mimic has a
conformational distribution similar to the natural disaccharide
Mana(1,2)Man. Two conformations, dubbed E (for Extended) and
S (for Stacked), are in fast equilibrium around the (pseudo)glyco-
sidic bonds and are characterized by two mutually exclusive NOE
contacts: the H1-H10 contact for the S conformer, and the H1-
H30eq contact for the E conformer (Fig. 3a, the unconventional
numbering of the cyclohexane ring was adopted for easier compar-
ison with natural sugars). A qualitative analysis of the NOE data
allowed deducing that the E conformer of 1 is the preferred confor-
mation in solution (D2O). Interestingly, the E conformation was
also the one observed in the X-ray of the DC-SIGN:1 complex.27
A similar analysis performed on 2 (R = H, D2O, 500 MHz)
showed an intense H1-H30eq cross-peak (Fig. 4), while the H1-H10
contact was revealed as a weak cross-peak (Fig. 4, inset) using
800 ms mixing time. A conformational search of 2 performed with
the MM3⁄ force field supported the existence of both S and E con-
formers of similar strain energy (Fig. 3b. Both R = Me and R = H
were calculated, obtaining the same trends. Data are shown for
R = Me). However, due to the increased length of the CAS bond rel-
ative to the CAO bond, the calculated H1-H10 distance in the S con-
formation of 2 (S in Fig. 3b) is 3.1 Å, as opposed to 2.6 Å in 1
(Fig. 3a), in qualitative agreement with a reduced intensity of the
H1-H10 cross-peak. Overall, the data are consistent with both the
pseudo-1,2-dimannoside 1 and the pseudo-thio-1,2-dimannoside
2 populating the same conformational space and mimicking the
conformational features of the native Mana(1,2)Man sugar.2.3. Surface plasmon resonance inhibition studies with DC-SIGN
In order to investigate the biological activity of the pseudo-thio-
1,2-dimannoside and compare it to the O-analog, compounds 2
(R = H) and 11 were tested by a well-established Surface Plasmon
Resonance (SPR) inhibition assays.27 In this test, increasing concen-
trations of the glycomimetics are used to inhibit the binding of
DC-SIGN ECD (extra cellular domain) to mannosylated BSA immo-
bilized on an SPR sensor chip. The calculated IC50 values for 1
(R = CH2CH2N3), 2 and 11 in the same campaign (720 lM,
776 lM and 776 lM, respectively) are remarkably similar to one
another, showing that the replacement of the glycosidic oxygen
atom with a sulfur atom is not detrimental to the binding affinity
Fig. 3. (a) Stacked (S) and Extended (E) conformations of (a) the pseudo-1,2-
dimannoside 1. (b) the pseudo-thio-1,2-dimannoside 2. The mutually exclusive
NOE contacts defining the conformation are indicated by arrows.
Fig. 2. Characterization of 5. Coupling constant analysis (CD3OD) shows that the
conformation of the cyclohexane chair depicted here corresponds to 90% of the
conformer population. The unconventional numbering of the cyclohexane ring was
adopted for easier comparison with the natural Mana(1,2)Man disaccharide.
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Scheme 3. Proposed mechanism for the one-pot epoxide opening reaction.
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sides variously substituted at position 10 had shown a minor influ-
ence on DC-SIGN affinity, as expected on the basis of the X-ray
structure of the complex, which shows the 10 ether chain pointing
away from the protein binding site. This was confirmed for thethio-analog by comparison of the IC50 measured for 2 and 11.
The low, submillimolar activity of these monovalent ligands is
characteristic of oligosaccharide-protein interactions and is over-
come, both in Nature and in the development of active antagonists,
by exploiting multivalent interactions.8
3. Discussion and conclusions
Antagonists of the C-type lectin DC-SIGN are promising
therapeutic agents against viral infections.9 Mimics of the
1,2-mannobioside disaccharide unit, Mana(1,2)Man, presented as
appropriate multivalent constructs have shown an ability to inter-
act with the protein and to antagonize DC-SIGNmediated HIV trans
infection of CD4+ T lymphocytes. Mimicry of the Mana(1,2)Man
unit has been obtained with pseudo-1,2-dimannoside 1, where
the reducing end mannose is replaced by a conformationally
locked cyclohexanediol.9 More recently, we and others have shown
that similar results can be obtained using a real D-carbamannose
unit.28 Mimic 1, as well as the carbamannose analog, are slower
substrates than the natural disaccharide for hydrolytic enzymes
and thus have a better outlook as drug candidates. The group of
Borbás has recently reported the synthesis of a thio-linked Mana
(1,2)Man disaccharide by photoinduced hydrothiolation of a
2,3-unsaturated glucoside29 and its use for the synthesis of self-
assembling glycoconjugates.30
We have presented here the pseudo-thiodisaccharide analog of
1, 2, which is expected to be further stabilized against enzymatic
and chemical hydrolysis. The compound was synthesized in a
straightforward one-pot process from tetra-O-acetylmannose-1-
thioacetate 4 and epoxide 3, both easily accessible substrates.
Fig. 4. NOESY spectrum (500 MHz, D2O, 300 K, 800 ms of mixing time) of compound 2 (R = H) performed with solvent suppression.
Fig. 5. Inhibition of DC-SIGN ECD binding to immobilized ManBSA by 1, 2 (R = H), and 11 was measured by SPR.
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ides with glycosyl thiols has been reported before,31 but we have
coupled this reaction with an in situ generation of the reactive
thiolate from the anomeric thioacetate. This procedure implies
several advantages compared to the classical glycosylation condi-
tions. First of all, the one-pot synthesis allows improving the
efficiency of the process whereby the reactants are subjected to
successive transformations in the same reaction vessel, minimizing
the purification steps. Moreover, the S-linkage can be formed
avoiding the strict requirements for the standard glycosylation
reaction (low reaction temperature, anhydrous conditions, etc.)
and minimizing formation of disulfides by oxidation of the glyco-
sidic thiol.
Conformational analysis of the pseudo-thio-1,2-dimannoside 2
by NMR-NOESY studies, supported by molecular modeling,
strongly suggest that the molecule is a bona fide structural mimic
of the natural Mana(1,2)Man sugar and shares the conformational
features of the O-linked analog. Interaction studies with DC-SIGN,
performed by Surface Plasmon Resonance confirm that the
molecule acts as a DC-SIGN antagonist and has the same potency
of analog 1.
Last, but not least, we were able to equip this molecule with a
stable, azido-terminated ester tether which survived Zemplén
deprotection conditions and will be instrumental for the synthesisof multivalent constructs. Multivalent presentation of glycomimetic
ligands is a well-established approach to circumvent the intrinsi-
cally low affinity of sugar-protein interactions and obtain highly
active antagonists. Given its easy synthesis and expected metabolic
stability, ligand 2 has the potential to replace 1 and its derivatives
in the construction of multivalent DC-SIGN antagonists with
antiviral action.
4. Experimental
4.1. General information
Chemicals were purchased from commercial sources and used
without further purification, unless otherwise indicated. When
anhydrous conditions were required, the reactions were performed
under nitrogen atmosphere. Anhydrous solvents were purchased
from Sigma-Aldrich. Reactions were monitored by analytical
thin-layer chromatography (TLC) performed on Silica Gel 60 F254
plates (Merck) with UV detection (254 nm) and/or staining with
ceric ammonium molybdate acid solution, potassium perman-
ganate alkaline solution. Silica gel 60 (40–63 lm) (Merck) was
used for flash column chromatography. NMR experiments were
recorded on a Bruker AVANCE-400 MHz instrument at 298 K or a
Bruker AVANCE-500 MHz at 300 K. Chemical shifts (d) are reported
5146 A. Tamburrini et al. / Bioorganic & Medicinal Chemistry 25 (2017) 5142–5147in ppm. The 1H and 13C NMR resonances of compounds were
assigned with the assistance of COSY and HSQC experiments.
Multiplicities are assigned as s (singlet), d (doublet), t (triplet), q
(quartet), quint (quintet), m (multiplet). Mass spectra were
recorded on Apex II ICR FTMS (ESI ionization-HRMS), Waters
Micromass Q-TOF (ESI ionization-HRMS) or ThermoFischer LCQ
apparatus (ESI ionization). Specific optical rotation values were
measured using a Perkin-Elmer 241, at 589 nm in a 1 dm cell.
4.2. NMR NOESY experiments
NMR spectra of 2 (R = H) were obtained using 5 mg of 2 in
500 lL D2O (24 mM). NOESY spectra were acquired using a Bruker
500 MHz instrument at 300 K. Spectra (8 scans and 256 incre-
ments) were collected using three mixing times (300, 600 and
800 ms). Water suppression was achieved by excitation–sculpting
pulse sequence.
4.3. Synthesis
Compound 3 was prepared as previously described.16 Com-
pound 4 was prepared from commercially available penta-O-
acetylmannopyranose 6 following a reported procedure23 and
2,2-dimethyl-3-azido-propanoylchloride 12 was synthesized from
commercially available 2,2-dimethyl-3-chloro-propanoic acid
according to Sewald,26 with modifications.
4.3.1. 2,3,4,6-Tetra-O-acetyl-1-S-acetyl-a-D-mannopyranose 4
To a solution of penta-O-acetylmannopyranose 6 (1.021 g,
2.62 mmol) in dry CH2Cl2 (1.75 mL), thioacetic acid 7 (558 lL,
7.85 mmol) was added under nitrogen atmosphere. TMSOTf
(473 lL, 2.62 mmol) was added dropwise at 0 C and the resulting
mixture was stirred at room temperature overnight. After 15 h, TLC
showed complete conversion of the starting material. The reaction
mixture was diluted with CH2Cl2 and washed with satd aq NaHCO3
and H2O. The organic phase was dried over anhydrous Na2SO4, fil-
tered and concentrated in vacuo. The crude material was purified
by flash chromatography (2:8 CH2Cl2:iPr2O) to afford 4 (654 mg,
1.61 mmol) in 61% yield. TLC: Rf = 0.35 (2:8 CH2Cl2:iPr2O); 1H
NMR (400 MHz, CDCl3): d = 5.93 (d, J = 1.6 Hz, 1H), 5.33 (dd,
J = 10 Hz, 1H), 5.31 (dd, J = 3.2 Hz, J = 1.6 Hz, 1H), 5.08 (dd,
J = 10 Hz, J = 3.2 Hz, 1H), 4.26 (dd, J = 12.4 Hz, 4.8 Hz, 1H), 4.05
(dd, J = 12.4 Hz, 2.4 Hz, 1H), 3.91 (ddd, J = 10 Hz, 4.8 Hz, 2.4 Hz,
1H), 2.41 (s, 3H), 2.16, 2.06, 2.02, 1.97 (s, 3H each); 13C NMR
(100 MHz, CDCl3): d = 190.3, 170.5, 169.8, 169.7, 169.4, 80.1, 72.4,
70.9, 69.8, 65.6, 62.1, 31.2, 20.8, 20.6, 20.6, 20.5.
4.3.2. Compound 5
Diethylamine (75 lL, 0.72 mmol) was added to a solution of
2,3,4,6-tetra-O-acetyl-1-S-acetyl-a-D-mannopyranose 4 (200 mg,
0.49 mmol) and epoxide 3 (81 mg, 0.38 mmol) in dry DMF
(630 lL). The reaction mixture was stirred for 4 h, then diluted
with EtOAc, washed with 1 M HCl and H2O. The organic phase
was dried over anhydrous Na2SO4, filtered and concentrated in
vacuo. The crude material was purified by flash chromatography
(4:6 Hex:EtOAc) to afford 5 (149 mg, 0.26 mmol) in 68% yield.
TLC: Rf = 0.3 (4:6 Hex:EtOAc); [a]D14 (CHCl3, c 1.03): +68; 1H NMR
(400 MHz, CDCl3): d = 5.37 (dd, J = 3.2 Hz, 1.5 Hz, 1H), 5.33 (d,
J = 1.3 Hz, 1H), 5.26 (t, J = 9.9 Hz, 1H), 5.19 (dd, J = 9.9 Hz, 3.2 Hz,
1H), 4.40–4.34 (m, 1H), 4.24 (dd, J = 12 Hz, 6.4 Hz, 1H), 4.11 (dd,
J = 12.3 Hz, 2.6 Hz, 1H), 3.86–3.78 (m, 1H), 3.71 (s, 3H), 3.69 (s,
3H), 3.22–3.14 (m, 1H), 3.10–2.98 (m, 2H), 2.2–2.11 (m, 4H), 2.08
(s, 3H), 2.05 (s, 3H), 1.99 (s, 3H), 1.93–1.76 (m, 2H); 1H NMR
(400 MHz, CD3OD): d = 5.45 (bs, 1H); 5.37 (dd, J = 3.2 Hz, 1.5 Hz,
1H), 5.24 (t, J = 9.9 Hz, 1H), 5.19 (dd, J = 9.9 Hz, 3.2 Hz, 1H), 4.38–
4.32 (m, 1H), 4.25 (dd, J = 12 Hz, 6.4 Hz, 1H), 4.12 (dd, J = 12 Hz,2.6 Hz, 1H), 4.0 (q, J = 3.3 Hz, 1H), 3.68 (s, 6H), 3.20 (q, J = 3.6 Hz,
1H), 3.05 (dt, J = 11 Hz, 5.5 Hz, 1H), 2.92 (dt, J = 11 Hz, 3.8 Hz,
1H), 2.22–2.32 (m, 1H), 2.15 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H),
2.06–2.00 (m, 1H) 1.97 (s, 3H), 1.97–1.88 (m, 2H); 13C NMR
(100 MHz, CDCl3): d = 174.1, 173.8, 170.6, 169.9, 169.7, 169.6,
82.6, 71.1, 69.5, 69.3, 69.1, 66.3, 62.5, 52.2, 52.1, 48.7, 40.3, 39.6,
31.3, 28.6, 20.8, 20.6, 20.6, 20.5; MS (ESI) calcd for C24H34O14S [M
+Na]+ m/z: 601.16, found 601.42; HR-MS (ESI) calcd for
C24H34O14S [M+Na]+ m/z: 601.15615, found 601.15571.
4.3.3. Compound 10
To a solution of compound 5 (40 mg, 0.069 mmol) in dry pyri-
dine (150 lL), DMAP (8 mg, 0.069 mmol) and pivaloyl chloride
(43 lL, 0.35 mmol) were added. The mixture was stirred at room
temperature under nitrogen atmosphere. After 5 h, a second
aliquot of pivaloyl chloride (25 lL, 0.21 mmol) was added. After
reaction completion (24 h, monitored by TLC, 6:4 Hex:EtOAc) the
mixture was diluted with EtOAc, washed with 1 M HCl, H2O and
satd aq NaHCO3. The organic layer was dried over anhydrous
Na2SO4 and concentrated under reduced pressure. Flash chro-
matography (6:4 Hex:EtOAc) yielded product 10 (27 mg) in 59%
yield. TLC: Rf 0.3 (6:4 Hex:EtOAc); [a]D22 (CHCl3, c 1.61): +75; 1H
NMR (400 MHz, CDCl3): d = 5.38 (d, J = 1.5 Hz, 1H), 5.35 (dd,
J = 3.2 Hz, 1.6 Hz, 1H), 5.29 (t, J = 9.7 Hz, 1H), 5.18 (dd, J = 10.0 Hz,
3.3 Hz, 1H), 5.08–5.04 (m, 1H), 4.36–4.27 (m, 2H), 4.16–4.07 (m,
1H), 3.7 (s, 3H), 3.69 (s, 3H), 3.34–3.29 (m, 1H), 3.01–2.87 (m,
2H), 2.15 (s, 3H), 2.13–2.00 (m, 10H), 1.99 (s, 3H) 1.2 (s, 9H); 13C
NMR (100 MHz, CDCl3): d = 177.0, 174.2, 174.1, 170.5, 169.8,
169.7, 169.5, 82.9, 70.8, 69.7, 69.6, 69.2, 65.9, 62.3, 52.0, 52.0,
43.6, 39.6, 39.5, 38.8, 28.7, 27.9, 27.0, 20.8, 20.6, 20.5, 20.5; MS
(ESI) calcd for C29H42O15S [M+Na]+ m/z: 685.21, found 685.29.
4.3.4. 3-Azido-2,2-dimethylpropanoyl chloride 12
2,2-Dimethyl-3-chloro-propanoic acid (400 mg, 2.97 mmol)
was dissolved in dry DMF (14.6 mL) and NaN3 (990 mg, 15.2 mmol)
was added. The mixture was stirred at 50 C under nitrogen
atmosphere. After 3 days, the reaction was allowed to reach room
temperature. The mixture was diluted with CH2Cl2 and filtered
over a celite pad to remove unreacted NaN3. The solvent was evap-
orated at reduced pressure giving 3-azido-2,2-dimethylpropanoic
acid in quantitative yield (425 mg). The analytical data were fully
consistent with those reported in the literature32 (1H NMR
(400 MHz, CDCl3): d = 3.42 (s, 2H), 1.25 (s, 6H)) and the compound
was used without further purification.
The crude azide (143 mg, 1.00 mmol) was dissolved in dry
CH2Cl2 (3.3 mL) and oxalyl chloride (254 lL, 2.00 mmol) was added
drop wise to the solution. After the addition of one drop of dry
DMF, the mixture was refluxed for 3 h. The solution was cooled
to room temperature and the solvent was carefully removed in
vacuo to yield 3-azido-2,2-dimethylpropanoyl chloride 12. The
complete conversion was confirmed by NMR analysis and the pro-
duct was used in the next step without further purification. 1H
NMR (400 MHz, CDCl3): d = 3.53 (s, 2H), 1.35 (s, 6H).
4.3.5. Compound 13
To a solution of compound 5 (30 mg, 0.052 mmol) in dry CH2Cl2
(400 lL) and Et3 N (16 lL, 0.117 mmol), DMAP (2 mg, 0.015 mmol)
was added. The solution was cooled to 0 C and compound 12
(19 mg, 0.116 mmol) was added. The mixture was stirred at room
temperature under nitrogen atmosphere. After reaction comple-
tion (3 h, monitored by TLC, 1:1 Hex:EtOAc) the mixture was
diluted with CH2Cl2, washed with satd aq NaHCO3 and 1 M HCl.
The organic layer was dried over anhydrous Na2SO4 and concen-
trated under reduced pressure. Flash chromatography (6:4 Hex:
EtOAc) yielded product 13 (29 mg) in 79% yield. TLC: Rf 0.5 (1:1
Hex:EtOAc); [a]D16 (CHCl3, c 1.08): +67; 1H NMR (400 MHz, CDCl3):
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J = 9.7 Hz, 3.6 Hz, 1H), 5.14–5.11 (m, 1H), 4.37–4.30 (m, 2H), 4.15–
4.07 (m, 1H), 3.71 (s, 3H), 3.71 (s, 3H), 3.42 (s, 2H), 3.36–3.33 (m,
1H), 3.03–2.89 (m, 2H), 2.17 (s, 3H), 2.14–2.06 (m, 4H), 2.18 (s,
3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.23 (s, 3H), 1.23 (s, 3H); 13C NMR
(100 MHz, CDCl3): d = 174.6, 174.5, 174.3, 170.8, 170.2, 170.0,
169.9, 83.3, 71.1, 70.9, 70.0, 69.6, 66.3, 62.6, 59.9, 52.4, 44.2,
43.8, 40.0, 39.9, 29.1, 28.2, 23.3, 23.3, 21.1, 20.9, 20.9, 20.9; MS
(ESI) calcd for C29H41N3O15S [M+Na]+ m/z: 726.2; found 726.8.
4.3.6. General procedure for the Zemplén deacetylation
A MeONa/MeOH solution was added to the substrate dissolved
in dry MeOH under nitrogen atmosphere (substrate and MeONa
final concentration 0.02 M) and the reaction mixture was stirred
at room temperature. After completion, (approx. 10 min, moni-
tored by TLC) the reaction was quenched with AMBERLITE IR-120
H+ till neutral pH, the resin was filtered off and the solvent was
evaporated at reduced pressure, obtaining the pure product.
4.3.6.1. Pseudo-thio-1,2-dimannoside 2 (R = H). TLC: Rf 0.4 (8:2
CH2Cl2:MeOH); [a]D19 (MeOH, c 0.51): +155; 1H NMR (400 MHz,
D2O): 5.38 (d, J = 1.5 Hz, 1H), 4.12–4.07 (m, 1H), 4.06 (dd,
J = 1.5 Hz, 3.2 Hz, 1H), 3.95 (ddd, J = 1.9 Hz, 6.2 Hz, 9.0 Hz, 1H),
3.85 (dd, J = 2.2 Hz, 12.4 Hz, 1H), 3.77–3.71 (m, 2H), 3.70 (s, 3H),
3.69 (s, 3H), 3.64 (dd, J = 9.8 Hz, 9.5 Hz, 1H), 3.25–3.19 (m, 1H),
3.06–2.95 (m, 2H), 2.27–2.16 (m, 1H), 2.11–2.03 (m, 1H), 2.00–
1.92 (m, 2H); 13C NMR (100 MHz, D2O): d = 177.3, 177.0, 84.9,
73.4, 71.7, 71.0, 67.7, 67.0, 60.8, 52.6, 45.4, 40.0, 39.0, 29.9, 27.5;
HR-MS (ESI) calcd for C16H26O10S [M+Na]+ m/z: 433.11389; found
433.11346.
4.3.6.2. Compound 11. TLC: Rf 0.24 (9:1 CH2Cl2:MeOH); [a]D20
(MeOH, c 1.01): +128; 1H NMR (400 MHz, D2O): 5.41 (d,
J = 1.1 Hz, 1H), 5.11–5.08 (m, 1H), 4.08 (dd, J = 1.5 Hz, 3.3 Hz, 1H),
3.95 (ddd, J = 2.4 Hz, 5.8 Hz, 9.4 Hz, 1H), 3.85 (dd, J = 2.4 Hz,
12.5 Hz, 1H), 3.79–3.72 (m, 2H), 3.71 (s, 3H), 3.70 (s, 3H), 3.69–
3.63 (m, 1H), 3.42–3.38 (m, 1H), 3.05–2.92 (m, 2H), 2.23–2.01
(m, 4H), 1.21 (s, 9H); 13C NMR (100 MHz, D2O): d = 180.3, 176.8,
176.8, 85.3, 73.6, 71.7, 71.0, 70.6, 66.8, 60.6, 52.7, 52.7, 42.8,
39.9, 39.6, 38.7, 28.4, 27.3, 26.2; HR-MS (ESI) calcd for
C21H34O11S [M+Na]+ m/z: 517.17140; found 517.17166.
4.3.6.3. Compound 14. TLC: Rf 0.37 (9:1 CH2Cl2:MeOH); [a]D20
(MeOH, c 0.81): +112; 1H NMR (400 MHz, MeOD): d = 5.40–5.36
(m, 1H), 5.17–5.12 (m, 1H), 3.95 (dd, J = 1.6 Hz, 3.2 Hz, 1H), 3.88–
3.81 (m, 2H), 3.75 (dd, J = 6.0 Hz, 12.2 Hz, 1H), 3.72–3.68 (m, 1H),
3.69 (s, 3H), 3.67 (s, 3H), 3.62 (dd, J = 3.2 Hz, 9.2 Hz, 1H), 3.50 (s,
2H), 3.43–3.38 (m, 1H), 3.00–2.89 (m, 2H), 2.19–2.10 (m, 2H),
2.08–2.02 (m, 2H), 1.24 (s, 6H). 13C NMR (100 MHz, MeOD):
d = 176.1, 176.0, 176.0, 87.1, 75.7, 73.6, 73.1, 72.4, 68.5, 62.5,
60.8, 52.6, 52.6, 45.0, 44.1, 41.1, 40.9, 30.0, 29.0, 23.3, 23.3;
HR-MS (ESI) calcd for C21H33N3O11S [M+Na]+ m/z: 558.17280;
found 558.17371.
4.4. Surface plasmon resonance (SPR) analysis
The extracellular domain (ECD) of DC-SIGN (residues 66-404)
was overexpressed and purified as previously described.33 The
SPR experiments were performed on a BIAcore T200 using a CM3
sensor chip. Flow cells were activated as described.34 Flow cell
one was functionalised with BSA and blocked with ethanolamine
and subsequently used as a control surface. Flow cells 2 and 3 weretreated with BSA-Mana1-3[Mana1-6]Man (Dextra) (60 lg/ml) in
10 mM NaOAc pH 4 to reach different binding densities and
blocked with ethanolamine. The final densities on flow cells 2
and 3 were 2579 and 2923 RU, respectively. The affinity of the
various compounds for DC-SIGN ECD were evaluated via an estab-
lished inhibition assay35 in which DC-SIGN ECD was injected at
20 lM alone or in the presence of increasing concentration of
inhibitors (ranging from 0 to 5 mM). Injections were performed
at 5 lL/min using 25 mM Tris-HCl pH 8, 150 mMNaCl, 4 mM CaCl2,
0,05% P20 surfactant as running buffer. The surface was regener-
ated by the injection of 50 mM EDTA.
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